Search Clinical Trials
598,375 trials
ID
Status
Phase
Title
Sponsor
NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTAstraZenecaRecruitingPhase 3
NCT07764978Recruiting
Phase 3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTAstraZeneca
NCT07765043
Electromagnetic Therapy for Cervicogenic DysphagiaUmm Al-Qura UniversityCompletedNot Applicable
NCT07765043Completed
Not Applicable
Electromagnetic Therapy for Cervicogenic DysphagiaUmm Al-Qura University
NCT07765212
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)Eva M.M. StrijbisNot Yet RecruitingPhase 2
NCT07765212Not Yet Recruiting
Phase 2
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progre...Eva M.M. Strijbis
NCT07765225
Ultrasonographic Evaluation of Cosmetic Keratolytic Treatment of Foot Calluses and CornsWroclaw University of Health and Sport SciencesCompletedNot Applicable
NCT07765225Completed
Not Applicable
Ultrasonographic Evaluation of Cosmetic Keratolytic Treatment of Foot Calluses a...Wroclaw University of Hea...
NCT07765940
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate CancerRadAlliance Therapeutics, IncNot Yet RecruitingPhase 1
NCT07765940Not Yet Recruiting
Phase 1
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Can...RadAlliance Therapeutics,...
NCT07765017
Early Mobilization and Prolonged ICU Stay in Postoperative PatientsAnkara Training and Research HospitalNot Yet Recruiting
NCT07765017Not Yet Recruiting
—
Early Mobilization and Prolonged ICU Stay in Postoperative PatientsAnkara Training and Resea...
NCT07764861
A Open-Label Phase in Participants With Multiple MyelomaInnovent Biologics (Suzhou) Co. Ltd.Not Yet RecruitingPhase 2
NCT07764861Not Yet Recruiting
Phase 2
A Open-Label Phase in Participants With Multiple MyelomaInnovent Biologics (Suzho...
NCT07765901
Comparison of Postoperative Sensitivity Following Bulk-Fill and Conventional Incremental Composite Restorations: A Randomized Controlled Trial at Tertiary Care Hospital of PeshawarPrime FoundationNot Yet RecruitingNot Applicable
NCT07765901Not Yet Recruiting
Not Applicable
Comparison of Postoperative Sensitivity Following Bulk-Fill and Conventional Inc...Prime Foundation
NCT07766161
Informing Implementation of a Circadian-Focused Intervention for Postpartum DepressionAmerican Academy of Sleep MedicineRecruitingNot Applicable
NCT07766161Recruiting
Not Applicable
Informing Implementation of a Circadian-Focused Intervention for Postpartum Depr...American Academy of Sleep...
NCT07766447
Long-term Medical Impact of War Injuries on Military PersonnelDirection Centrale du Service de Santé des ArméesNot Yet RecruitingNot Applicable
NCT07766447Not Yet Recruiting
Not Applicable
Long-term Medical Impact of War Injuries on Military PersonnelDirection Centrale du Ser...
NCT07765667
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARCSixth Affiliated Hospital, Sun Yat-sen UniversityNot Yet RecruitingPhase 2
NCT07765667Not Yet Recruiting
Phase 2
NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARCSixth Affiliated Hospital...
NCT07766551
Construction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI)China National Center for Cardiovascular DiseasesNot Yet Recruiting
NCT07766551Not Yet Recruiting
—
Construction and Validation of a Coronary Artery Disease-Specific Large Language...China National Center for...
NCT07765888
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaPfizerNot Yet RecruitingPhase 3
NCT07765888Not Yet Recruiting
Phase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moder...Pfizer
NCT07765823
ROLE OF N-ACETYLCYSTEINE IN NON-ACETAMINOPHEN-INDUCED LIVER FAILUREKing Edward Medical UniversityRecruitingNot Applicable
NCT07765823Recruiting
Not Applicable
ROLE OF N-ACETYLCYSTEINE IN NON-ACETAMINOPHEN-INDUCED LIVER FAILUREKing Edward Medical Unive...
NCT07764562
Development and Validation of an Ultrasound-Based Difficult Cannulation Risk Score for Pre-procedural Internal Jugular Vein Catheterization in Critically Ill Patients: A Prospective Observational Cohort StudyAntalya Health Sciences UniversityRecruiting
NCT07764562Recruiting
—
Development and Validation of an Ultrasound-Based Difficult Cannulation Risk Sco...Antalya Health Sciences U...
NCT07766265
NEST: A Group Intervention for Parents With Complex PTSDSt.Gallen University of Applied SciencesNot Yet RecruitingNot Applicable
NCT07766265Not Yet Recruiting
Not Applicable
NEST: A Group Intervention for Parents With Complex PTSDSt.Gallen University of A...
NCT07766252
CCHW-delivered CFH-based Cancer Prevention Program Among Chinese AmericansTexas A&M UniversityCompletedNot Applicable
NCT07766252Completed
Not Applicable
CCHW-delivered CFH-based Cancer Prevention Program Among Chinese AmericansTexas A&M University
NCT07765433
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract CancerECOG-ACRIN Cancer Research GroupNot Yet RecruitingPhase 2
NCT07765433Not Yet Recruiting
Phase 2
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared...ECOG-ACRIN Cancer Researc...
NCT07765485
Effect of Pyramidal Aerobic Training on Ventilatory Function in Cigarette SmokersCairo UniversityCompletedNot Applicable
NCT07765485Completed
Not Applicable
Effect of Pyramidal Aerobic Training on Ventilatory Function in Cigarette Smoker...Cairo University
NCT07765160
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese ParticipantsInnovent Biologics (Suzhou) Co. Ltd.Not Yet RecruitingPhase 1
NCT07765160Not Yet Recruiting
Phase 1
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Parti...Innovent Biologics (Suzho...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting4 (20%)
Completed4 (20%)
not_applicable9 (45%)
Phase 24 (20%)
Not Specified3 (15%)
Phase 32 (10%)
Phase 12 (10%)